Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical development and management of adverse events associated with FGFR inhibitors
Vivek Subbiah, Srđan Verstovšek
Cell Reports Medicine (2023) Vol. 4, Iss. 10, pp. 101204-101204
Open Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2
Heike Schönherr, Pelin Ayaz, Alexander M. Taylor, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 6
Open Access | Times Cited: 21
The evolving landscape of tissue‐agnostic therapies in precision oncology
Vivek Subbiah, Mohamed A. Gouda, Bettina Ryll, et al.
CA A Cancer Journal for Clinicians (2024) Vol. 74, Iss. 5, pp. 433-452
Open Access | Times Cited: 19
Preparation and Characterization of an Engineered FGF1 Conjugated to 161Tb for Targeting of FGFRs
Linlin Song, Michał Kostas, Jon K. Laerdahl, et al.
ACS Omega (2025) Vol. 10, Iss. 6, pp. 5730-5743
Open Access
The Role of Fibroblast Growth Factors in Viral Replication: FGF-2 as a Key Player
Danial Zareh, Reyhaneh Nekounam Ghadirli, Hao Zuo, et al.
IntechOpen eBooks (2025)
Closed Access
Activation of FGFR genes by genetic and epigenetic alterations in uterine leiomyomas
Vilja Jokinen, Aurora Taira, Åsa Kolterud, et al.
BJC Reports (2025) Vol. 3, Iss. 1
Open Access
Decoding driver and phenotypic genes in cancer: Unveiling the essence behind the phenomenon
Dequan Liu, Lei Liu, Xiaoman Zhang, et al.
Molecular Aspects of Medicine (2025) Vol. 103, pp. 101358-101358
Open Access
Case Series of Patients With FGFR1‐Related Pheochromocytoma and Paraganglioma With a Focus on Biochemical, Imaging Signatures and Treatment Options
Sakshi Jhawar, Abhishek Jha, Sara Talvacchio, et al.
Clinical Endocrinology (2025)
Open Access
Selective degradation of FGFR1/2 overcomes antiestrogen resistance in ER+ breast cancer with FGFR1/2 alterations
Yasuaki Uemoto, Chang-Ching Lin, Bingnan Wang, et al.
Cancer Letters (2025), pp. 217668-217668
Closed Access
Clinical advances and challenges in targeting FGF/FGFR signaling in lung cancer
Mei Peng, Jun Deng, Xiangping Li
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 3
Cost in the United States of FDA-approved small molecule protein kinase inhibitors used in the treatment of neoplastic and non-neoplastic diseases
Robert Roskoski
Pharmacological Research (2023) Vol. 199, pp. 107036-107036
Open Access | Times Cited: 8
FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies
Maxim Noeraparast, Katarina Krajina, Renate Pichler, et al.
Cancer Communications (2024) Vol. 44, Iss. 10, pp. 1189-1208
Open Access | Times Cited: 2
Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and Achondroplasia
Robert L. Hudkins, Eric Allen, Alexandra Balcer, et al.
Journal of Medicinal Chemistry (2024)
Closed Access | Times Cited: 2
Pemigatinib: A Review in Advanced Cholangiocarcinoma
James E. Frampton
Targeted Oncology (2024) Vol. 19, Iss. 1, pp. 107-114
Closed Access | Times Cited: 1
Engineering an fgfr4 knockout zebrafish to study its role in development and disease
Emma N. Harrison, Amanda N. Jay, Matthew R. Kent, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Emerging Targeted Therapies and Strategies to Overcome Resistance in Biliary Tract Cancers
Tarık Demır, Carolyn Moloney, Devalingam Mahalingam
Critical Reviews in Oncology/Hematology (2024) Vol. 199, pp. 104388-104388
Closed Access | Times Cited: 1
Durable benefit and slowdown in tumor growth dynamics with erdafitinib in a FGFR3-TACC3 fusion-positive IDH-wild type glioblastoma
Santiago Cabezas‐Camarero, Rebeca Pérez‐Alfayate, Carmen Polidura, et al.
Neuro-Oncology Advances (2024) Vol. 6, Iss. 1
Open Access | Times Cited: 1
The Clinical and Molecular Landscape of Rosette-Forming Glioneuronal Tumors
Zijiang Yang, Xiaobiao Zhang
Biomedicines (2024) Vol. 12, Iss. 10, pp. 2325-2325
Open Access | Times Cited: 1
The Complexity and Significance of Fibroblast Growth Factor (FGF) Signaling for FGF-Targeted Cancer Therapies
A. Nguyen, Caroline O. Facey, Bruce M. Boman
Cancers (2024) Vol. 17, Iss. 1, pp. 82-82
Open Access | Times Cited: 1
Erdafitinib and checkpoint inhibitors for first-line and second-line immunotherapy of hepatic, gastrointestinal, and urinary bladder carcinomas: Recent concept
Mohamed Wishahi
World Journal of Hepatology (2024) Vol. 16, Iss. 4, pp. 490-493
Open Access
Discovery and Characterization of Novel Fgfr1 Inhibitors in Triple-Negative Breast Cancer Via Hybrid Virtual Screening and Molecular Dynamics Simulations
Yuchen Wang, Zheyuan Shen, Ronfen Chen, et al.
(2024)
Closed Access
Skeletal overgrowth in a pre-pubescent child treated with pan-FGFR inhibitor
Fataneh Majlessipour, Gaohui Zhu, Nicole Baca, et al.
Heliyon (2024) Vol. 10, Iss. 11, pp. e30887-e30887
Open Access
The FGFR inhibitor Rogaratinib reduces microglia reactivity and synaptic loss in TBI
Rida Rehman, Albrecht Froehlich, Florian olde Heuvel, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Discovery and characterization of novel FGFR1 inhibitors in triple-negative breast cancer via hybrid virtual screening and molecular dynamics simulations
Yuchen Wang, Zheyuan Shen, Roufen Chen, et al.
Bioorganic Chemistry (2024) Vol. 150, pp. 107553-107553
Closed Access
A diverse landscape of FGFR alterations and co-mutations defines novel therapeutic strategies in pediatric low-grade gliomas
Eric Morin, April A. Apfelbaum, Dominik Sturm, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Successful Long-term Treatment with Modified Dose Pemigatinib in FGFR2-BICC1 Intrahepatic Cholangiocarcinoma: A Case Report
Kuan-Chang Lai, Ming-Huang Chen
Journal of Cancer Research and Practice (2024) Vol. 11, Iss. 3, pp. 114-117
Open Access
Page 1 - Next Page

Scroll to top